Verdiva Bio Deal History & Licensing Activity
Verdiva Bio is a life sciences. Over the past three years, Verdiva Bio has been involved in 2 licensing and acquisition transactions, with a primary focus on Peptides (2 deals). The company currently has 2 active clinical trials, primarily in Option Deals.
Deals (12mo)
2
Active Trials
2
Top Modality
Peptides
Focus Area
Option Deals
Verdiva Bio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Verdiva Bio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| incretin/GLP-1 metabolic assets | Sciwind Biosciences | Peptides | Preclinical | option | Jun 2025 |
| metabolic/obesity asset | Sciwind Biosciences | Other | Preclinical | co development | Jun 2025 |
Verdiva Bio Pipeline Focus
Therapeutic areas and modalities where Verdiva Bio is most active based on deal history and clinical trial data.
Verdiva Bio Clinical Pipeline
Verdiva Bio has 2 active clinical trials across 1 development phase.
2
Phase 2
See How Your Asset Matches Verdiva Bio's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Verdiva Bio Licensing & Deal Activity
Verdiva Bio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Verdiva Bio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Verdiva Bio include Option Deals (2 deals and trials), Codev Deals (2 deals and trials), and Metabolic (2 deals and trials). In terms of modality, Verdiva Bio has shown particular interest in peptides, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Verdiva Bio and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Verdiva Bio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.